H.C. Wainwright analyst Ed Arce maintained a Buy rating on Aurinia Pharmaceuticals (AUPH – Research Report) today. The company’s shares closed last Friday at $8.40.
According to TipRanks, Arce is a 4-star analyst with an average return of 6.6% and a 44.20% success rate. Arce covers the Healthcare sector, focusing on stocks such as CymaBay Therapeutics, Cidara Therapeutics, and Mirum Pharmaceuticals.
Aurinia Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $14.00.
See the top stocks recommended by analysts >>
Based on Aurinia Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $54.52 million and a GAAP net loss of $13.45 million. In comparison, last year the company earned a revenue of $55.78 million and had a GAAP net loss of $9.61 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aurinia Pharmaceuticals (AUPH) Company Description:
Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
Read More on AUPH:
- Aurinia Pharmaceuticals sees FY24 net product revenue $200M-$220M
- Aurinia Pharmaceuticals sees FY23 revenue about $176M, consensus $174.71M
- Aurinia Pharmaceuticals sees Q4 revenue about $45M, consensus $44.2M
- Aurinia Pharmaceuticals submits IND application to FDA for AUR200
- Aurinia Pharmaceuticals put volume heavy and directionally bearish
